A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Niraparib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms GALAHAD
- Sponsors Janssen Research & Development
- 27 Sep 2017 Planned End Date changed from 10 Oct 2019 to 31 Dec 2019.
- 10 Jun 2017 Biomarkers information updated
- 08 Jun 2017 Status changed from recruiting to suspended as Current participants remain active and on study treatment; new enrollment may resume pending review of data collected.